Inhibition of middle east respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13892-13899

  Ohnuma, Kei ^a   Haagmans, Bart L ^b   Hatano, Ryo ^a   Raj, V Stalin ^b   Mou, Huihui ^c   Iwata, Satoshi ^a   Dang, Nam H ^d   Bosch, Berend Jan ^c   Morimoto, Chikao ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL SURFACE PROTEIN; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ARTICLE; CORONAVIRUS; CORONAVIRUS INFECTION; DISEASE SEVERITY; ENZYME ACTIVITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INFECTIVITY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CORONAVIRIDAE; CORONAVIRIDAE INFECTIONS; DIPEPTIDYL PEPTIDASE 4; EPITOPE MAPPING; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS INTERNALIZATION;

EID: 84888037046     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02448-13     Document Type: Article

References (27)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820.
2. Enserink M. 2013. New coronavirus reveals some of its secrets. Science 340:17-18.
3. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish Z, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV):announcement of the Coronavirus Study Group. J. Virol. 87:7790-7792.
4. CDC. 2013. Update:severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)-worldwide, 2012-2013. MMWR Morb. Mortal. Wkly. Rep. 62:480-483.
5. WHO. 2013. Novel coronavirus infection- update. http://www.who.int/csr/don/2013_09_17_ncov/en/index.html.
6. de Wilde AH, Ray VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Barcena M, Haagmans BL, Snijder EJ, van den Hoogen BG. 2013. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J. Gen. Virol. 94:1749-1760.
7. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. 8 September 2013, posting date. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. doi:10.1038/nm.3362.
8. Mou H, Raj VS, van Kuppeveld FJM, Rottier PJM, Haagmans BL, Bosch BJ. 2013. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87:9379-9383.
9. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251-254.
10. Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, Dahlberg HN, Schlossman SF, Morimoto C. 1992. Cloning and functional expression of the T cell activation antigen CD26. J. Immunol. 149:481-486.
11. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. 2013. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368:2487-2494.
12. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, Müller MA, Haas W, Guberina H, Röhnisch T, Schmid-Wendtner M, Aldabbagh S, Dittmer U, Gold H, Graf P, Bonin F, Rambaut A, Wendtner C-M. 2013. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect. Dis. 13:745-751.
13. Guery B, Poissy J, El Mansouf L, Sejourne C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu D, Fontanet A, van der Werf S. 2013. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus:a report of nosocomial transmission. Lancet 381:2265-2272.
14. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF. 2013. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227-231.
15. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, Guo D, Fu L, Cui Y, Liu X, Arledge KC, Chen YH, Zhang L, Wang X. 2013. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23:986-993.
16. Dong RP, Tachibana K, Hegen M, Scharpe S, Cho D, Schlossman SF, Morimoto C. 1998. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. Mol. Immunol. 35:13-21.
17. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C. 2007. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin. Cancer Res. 13:4191-4200.
18. Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C. 1990. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J. Immunol. 145:3963-3971.
19. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. 1993. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261:466-469.
20. Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, Morimoto C. 1997. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J. Immunol. 159:6070-6076.
21. Ludwig K, Fan H, Dobers J, Berger M, Reutter W, Bottcher C. 2004. 3D structure of the CD26-ADA complex obtained by cryo-EM and single particle analysis. Biochem. Biophys. Res. Commun. 313:223-229.
22. Weihofen WA, Liu J, Reutter W, Saenger W, Fan H. 2004. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J. Biol. Chem. 279:43330-43335.
23. Ohnuma K, Dang NH, Morimoto C. 2008. Revisiting an old acquaintance:CD26 and its molecular mechanisms in T cell function. Trends Immunol. 29:295-301.
24. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C. 2007. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J. Biol. Chem. 282:10117-10131.
25. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. 2003. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 10:19-25.
26. WHO.2013. Middle East respiratory syndrome coronavirus(MERS-CoV)- update. http://www.who.int/csr/don/2013_05_31_ncov/en/index.html.
27. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen M, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TCT, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus ADME, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.